antimicrobi
peptid
amp
gain
import
effect
therapeut
altern
convent
antibiot
recent
shown
set
nine
synthet
antimicrobi
peptid
four
origin
thrombininduc
human
plateletderiv
antimicrobi
protein
name
five
synthet
repeat
argininetryptophan
rw
repeat
demonstr
antibacteri
activ
plasma
platelet
use
wr
strain
vaccinia
viru
vv
model
viru
envelop
viru
present
studi
test
nine
synthet
peptid
antivir
activ
cell
culturebas
standard
plaqu
reduct
assay
util
estim
antivir
effect
peptid
analysi
reveal
peptid
virucid
vv
demonstr
highest
antivir
activ
reduct
viral
titer
wherea
peptid
treatment
result
reduct
ec
valu
found
gml
gml
respect
vvspike
plasma
sampl
virucid
activ
close
reduct
overal
present
studi
constitut
new
proofofconcept
develop
peptid
therapeut
vaccinia
viru
infect
biothreat
scenario
vitro
viral
reduct
agent
publish
elsevi
bv
ever
sinc
discoveri
antimicrobi
peptid
amp
gain
attent
import
therapeut
intervent
altern
field
diseas
prevent
care
number
microb
brogden
hancock
sahl
oyston
et
al
zaiou
mainli
attribut
rise
microbi
drug
resist
associ
toxic
higher
product
cost
involv
convent
antimicrobi
drug
result
intens
research
field
last
decad
approxim
amp
far
list
amp
databas
brogden
hancock
sahl
oyston
et
al
zaiou
peptid
either
deriv
natur
microb
vertebr
includ
human
synthet
form
brogden
hancock
sahl
zaiou
amp
could
demonstr
antimicrobi
properti
either
singl
class
organ
ie
antibacteri
antivir
antiparasit
antifung
multipl
class
pathogen
mechan
action
mani
amp
includ
either
direct
microbicid
activ
indirect
action
block
inhibit
import
pathway
microbi
life
cycl
brogden
chan
et
al
hancock
sahl
oyston
et
al
zaiou
though
current
report
amp
known
either
antibacteri
antifung
peptid
number
antivir
peptid
slowli
go
amp
shown
effect
antivir
virus
influenza
viru
severeacut
respiratori
syndrom
coronaviru
sarscov
west
nile
viru
wnv
virus
bai
et
al
basu
et
al
chu
et
al
daher
et
al
guo
et
al
oyston
et
al
zaiou
interestingli
antivir
peptid
origin
either
elicit
due
immun
respons
host
viral
infect
virusencod
bai
et
al
basu
et
al
chu
et
al
daher
et
al
guo
et
al
oyston
et
al
zaiou
besid
two
class
amp
produc
mammalian
cell
cathelicidin
gallo
et
al
harder
et
al
two
cathelicidin
repres
famou
antimicrobi
peptid
demonstr
potent
antibacteri
antivir
antifung
properti
dorschner
et
al
howel
et
al
known
inhibit
replic
herp
simplex
viru
hsv
cytomegaloviru
cmv
vesicular
stomat
viru
vsv
influenza
viru
daher
et
al
mechan
action
peptid
suggest
involv
disrupt
microbi
membran
andor
penetr
microbi
membran
interfer
intracellular
function
brogden
harrison
ramshaw
howel
et
al
liu
et
al
tang
et
al
far
cathelicidin
caragenin
synthet
amp
peptid
mimet
broad
spectrum
antivir
eb
peptid
aptam
shown
possess
antivir
activ
vaccinia
viru
vv
ahm
et
al
altmann
et
al
harrison
ramshaw
howel
et
al
howel
et
al
howel
et
al
saccucci
et
al
recent
demonstr
antibacteri
activ
two
type
amp
thrombininduc
human
plateletderiv
antimicrobi
peptid
pd
argininetryptophan
rw
repeat
peptid
aerob
bacteri
contamin
encount
blood
product
mohan
et
al
structur
mechan
action
pd
rw
peptid
elucid
previous
detail
peptid
also
known
noncytotox
nonhemolyt
chan
et
al
liu
et
al
yeaman
et
al
yeaman
bayer
vaccinia
viru
use
model
test
method
decontamin
blood
product
found
rel
resist
solventdeterg
inactiv
method
select
viru
evalu
antivir
activ
pd
rw
peptid
lin
et
al
remington
et
al
robert
wu
snyder
present
studi
evalu
pd
rw
peptid
previous
evalu
bacteria
mohan
et
al
antivir
activ
vv
model
viru
envelop
virus
observ
pd
rw
peptid
demonstr
antivir
activ
vv
cell
cultur
well
spike
plasma
simian
kidney
epitheli
cell
line
vero
cell
atcc
manassa
va
cultur
dulbecco
modifi
eagl
medium
dmem
mediatech
herndon
va
contain
fetal
bovin
serum
fb
mm
lglutamin
mediatech
herndon
va
penicillinstreptomycin
invitrogen
gaithersberg
md
vaccinia
viru
wr
strain
kind
gift
b
moss
propag
vero
cell
describ
previous
jonestrow
et
al
kotwal
et
al
mohan
et
al
vv
seed
stock
prepar
infect
three
flask
vero
cell
jonestrow
et
al
kotwal
et
al
infect
cell
freezethaw
three
time
h
postinfect
hpi
follow
low
speed
centrifug
supernat
collect
estim
viral
titer
plaqu
assay
aliquot
store
c
use
jonestrow
et
al
kotwal
et
al
mohan
et
al
vv
infect
simian
kidney
epitheli
cell
antivir
analysi
perform
plate
total
nine
antimicrobi
peptid
synthes
cber
core
facil
four
consensu
sequenc
deriv
pd
peptid
amino
acid
length
microbicid
peptid
repeat
argtrp
amino
acid
tabl
liu
et
al
mohan
et
al
tang
et
al
yeaman
bayer
reconstitut
peptid
essenti
per
publish
protocol
except
solvent
use
mohan
et
al
pd
rw
peptid
reconstitut
phosphat
buffer
salin
pb
ph
sinc
pd
peptid
uniform
length
stock
solut
made
gl
reconstitut
lyophil
powder
pb
store
c
use
sinc
rw
peptid
variabl
length
stock
made
mm
concentr
peptid
dissolv
pb
ph
nine
amp
evalu
antivir
potenti
amp
test
differ
stage
viru
infect
pre
duringand
postinfect
vvinfect
without
peptid
taken
control
experi
perform
triplic
statist
analys
analyz
whether
amp
act
viru
andor
cell
vv
cell
treat
individu
nine
amp
prior
infect
assess
viral
titer
effect
amp
vv
perform
take
l
pfuml
concentr
wr
viru
mix
individu
peptid
made
final
volum
ml
dmem
incub
room
temperatur
h
final
concentr
pd
peptid
gml
wherea
rw
peptid
dilut
final
concentr
inoculum
ad
cell
maintain
plate
follow
viru
bind
cell
c
h
viru
inoculum
aspir
agar
overlay
contain
dmem
ad
cell
incub
h
jonestrow
et
al
kotwal
et
al
mohan
et
al
end
incub
period
agar
overlay
remov
cell
monolay
stain
crystal
violet
enumer
viru
plaqu
result
express
plaqueform
unit
pfu
ml
similarli
effect
pd
rw
peptid
cell
analyz
individu
treat
cell
peptid
h
concentr
follow
incub
peptid
mixtur
aspir
cell
wash
fresh
dmem
viru
infect
assess
inocul
ml
mixtur
vv
pfuml
onto
treatedcel
incub
h
c
viral
titer
measur
plaqu
assay
describ
l
pfuml
concentr
wr
viru
mix
individu
pd
rw
peptid
final
concentr
gml
respect
made
ml
fresh
dmem
mixtur
ad
directli
cell
cell
incub
c
h
follow
viru
bind
inoculum
aspir
agar
overlay
contain
dmem
ad
cell
cultur
plate
incub
c
h
jonestrow
et
al
kotwal
et
al
cell
monolay
stain
crystal
violet
viral
plaqu
describ
cell
maintain
cultur
plate
infect
ml
vv
inoculum
pfuml
incub
c
h
follow
viru
bind
inoculum
aspir
fresh
dmem
contain
individu
pd
peptid
final
concentr
gml
rw
peptid
ad
well
cell
cultur
plate
incub
c
follow
h
viru
infect
supernat
aspir
cell
monolay
freezethaw
thrice
extract
viru
particl
describ
previous
jonestrow
et
al
kotwal
et
al
viru
particl
extract
well
quantifi
plaqu
assay
describ
evalu
whether
pd
rw
peptid
microbicid
concentr
lower
gml
respect
serial
doubl
dilut
analysi
perform
peptid
sinc
pd
peptid
uniform
length
aa
constitut
gml
concentr
rw
peptid
though
vari
length
aa
henc
express
concentr
maintain
two
differ
concentr
express
unit
consist
previous
publish
work
mohan
et
al
final
concentr
pd
peptid
assay
gml
wherea
rw
peptid
concentr
pfuml
wr
viru
mix
individu
peptid
antivir
assay
perform
per
preinfect
protocol
describ
assess
whether
three
amp
would
maintain
antivir
activ
biolog
materi
human
plasma
sampl
spike
vv
peptid
test
activ
human
plasma
sampl
acquir
nih
blood
bank
bethesda
md
spike
pfu
vvwr
viru
peptid
incub
viru
inoculum
h
room
temperatur
test
antivir
activ
perform
plaqu
assay
describ
preinfect
experi
assay
describ
perform
minimum
three
time
mean
valu
sd
standard
deviat
calcul
use
microsoft
excel
statist
analys
perform
use
twotail
student
ttest
valu
consid
signific
p
doserespons
curv
ec
valu
peptid
estim
use
graphpad
tm
prism
softwar
order
evalu
stage
viru
infect
pd
rw
peptid
demonstr
antivir
activ
test
nine
amp
preinfect
incub
step
result
experi
reveal
preincub
amp
vv
abl
inhibit
viral
infect
fig
plateletderiv
peptid
abl
bring
vv
titer
peptid
abl
elicit
reduct
vv
titer
fig
remain
six
peptid
fig
antivir
activ
pd
rw
peptid
vv
preinfect
stage
wr
strain
vv
incub
pd
rw
peptid
gml
concentr
respect
h
rt
titer
measur
count
plaqu
cell
sinc
pd
peptid
uniform
length
aa
constitut
gml
wherea
rw
peptid
though
vari
length
aa
henc
express
concentr
two
differ
concentr
express
unit
maintain
consist
previous
publish
work
mohan
et
al
vv
infect
without
peptid
includ
control
peptid
demonstr
signific
p
indic
reduct
viral
titer
demonstr
antivir
activ
observ
control
group
observ
amp
abl
inhibit
vv
next
step
address
whether
amp
would
still
inhibit
vv
post
virusbind
step
postinfect
stage
analysi
post
virusbind
experi
reveal
none
pd
rw
peptid
abl
inhibit
viru
infect
signific
differ
viral
titer
test
control
group
fig
similarli
preand
postinfect
treatment
cell
pd
rw
peptid
signific
effect
viru
titer
control
peptidetr
group
fig
result
viral
titer
compar
vvinfect
lack
peptid
preinfect
experi
cell
incub
pd
rw
peptid
h
c
follow
wash
cell
infect
vv
virusbind
stage
experi
peptid
mix
individu
vv
mixtur
ad
cell
follow
incub
h
inoculum
aspir
agar
overlay
dmem
ad
postinfect
assay
perform
first
infect
cell
vv
h
ad
fresh
medium
contain
pd
rw
peptid
note
pd
rw
peptid
exhibit
signific
antivir
activ
p
three
stage
treatment
fig
doserespons
curv
estim
pd
rw
peptid
serial
doubl
dilut
analysi
perform
peptid
final
concentr
pd
peptid
assay
gml
wherea
rw
peptid
concentr
ml
wr
viru
pfuml
mix
individu
peptid
rt
h
follow
infect
cell
h
follow
viru
bind
agar
overlay
dmem
ad
cell
incub
c
h
viral
titer
estim
count
plaqu
four
differ
concentr
peptid
test
valu
deduc
use
graphpad
prism
softwar
peptid
concentr
repres
xaxi
log
scale
express
gml
concentr
express
analysi
reveal
valu
b
c
gml
gml
respect
order
evalu
minim
inhibitori
concentr
peptid
analysi
serial
doubl
dilut
peptid
effect
viru
inhibit
perform
doserespons
curv
gener
use
graphpad
prism
softwar
ec
valu
calcul
analysi
reveal
fig
fig
exhibit
ec
valu
gml
concentr
respect
hand
reveal
ec
dose
concentr
fig
sinc
peptid
alreadi
known
act
potent
antibacteri
agent
mohan
et
al
blood
product
analyz
whether
amp
could
inhibit
vv
vvspike
plasma
sampl
well
analysi
effect
peptid
vv
spike
plasma
sampl
reveal
potent
peptid
viru
inhibit
gml
concentr
peptid
hand
demonstr
reduct
viru
titer
gml
concentr
fig
abl
inhibit
vv
concentr
fig
previous
report
proofofconcept
usag
pd
rw
peptid
bactericid
agent
experiment
contamin
blood
product
mohan
et
al
ideal
use
antimicrobi
agent
exhibit
broadspectrum
antimicrobi
activ
viz
antibacteri
antivir
antifung
antiparasit
henc
present
studi
evalu
efficaci
amp
vaccinia
viru
reduct
experiment
infect
plasma
though
current
viru
inactiv
procedur
consid
highli
effici
transmiss
risk
due
virus
said
minim
possibl
still
exist
order
address
hypothet
possibl
occurr
select
vaccinia
viru
model
viru
pose
consider
challeng
resist
viru
solventdeterg
inactiv
method
lin
et
al
remington
et
al
robert
srinivasan
et
al
wu
snyder
nine
amp
test
three
peptid
exhibit
virucid
activ
vaccinia
viru
three
peptid
also
exhibit
potent
bactericid
activ
plasma
platelet
store
plasma
mohan
et
al
mechan
action
fig
antivir
activ
pd
rw
peptid
vv
spikedplasma
sampl
human
plasma
sampl
spike
pfu
vvwr
viru
incub
peptid
individu
h
test
antivir
activ
infect
cell
measur
viru
titer
perform
plaqu
assay
describ
preinfect
experi
note
treatment
result
reduct
viral
titer
p
indic
amp
bacteria
well
known
mechan
action
virus
yet
clearli
understood
liu
et
al
yeaman
bayer
antimicrobi
peptid
report
varieti
virus
includ
influenza
viru
sar
cov
wnv
hsv
mani
other
bai
et
al
basu
et
al
chu
et
al
guo
et
al
precis
mechan
action
variou
amp
similar
differ
virus
amp
could
even
stagespecif
action
differ
virus
may
act
extracellular
viru
may
intracellular
form
time
viru
releas
bai
et
al
basu
et
al
chu
et
al
guo
et
al
analysi
pd
rw
peptid
indic
three
peptid
exhibit
antivir
activ
viru
vitro
condit
peptid
effect
vv
bound
cell
membran
postinfect
interestingli
pretreat
cell
pd
rw
peptid
advers
affect
viru
titer
suggest
peptid
affect
viru
entri
may
abl
penetr
cell
report
recent
test
amp
snyder
dowdi
analysi
vvspike
plasma
sampl
confirm
peptid
abl
inhibit
viru
abl
retain
antivir
activ
biolog
fluid
well
one
would
argu
peptid
provid
reduct
vv
titer
effect
therapeut
agent
could
make
differ
blood
transfus
set
blood
donor
deferr
take
care
high
titer
symptomat
individu
inadvert
collect
blood
asymptomat
individu
ie
low
titer
scenario
reduct
vv
particl
less
particl
would
certainli
make
differ
peptid
achiev
reduct
viru
present
studi
highest
concentr
pd
rw
peptid
test
gml
respect
base
previou
experi
bacteria
mohan
et
al
regardless
whether
substanti
risk
acquir
vv
blood
product
demonstr
antivaccinia
properti
amp
plasma
sampl
promis
antivir
potenc
amp
may
potenti
applic
observ
caragenin
topic
therapi
poxvir
infect
howel
et
al
interestingli
caragenin
synthet
antimicrobi
compound
design
mimic
structur
function
endogen
amp
howel
et
al
futur
applic
amp
potenti
challeng
scenario
includ
treatment
variou
microbi
infect
especi
drugresist
one
system
administr
groneberg
et
al
pertin
small
anim
test
amp
would
provid
evid
applic
peptid
addit
reveal
peptid
clearanc
safeti
aspect
amp
vivo
distinct
advantag
pd
rw
peptid
nonimmunogen
noncytotox
nonhemolyt
thu
minim
safeti
concern
addit
sinc
amp
synthet
easi
produc
larg
quantiti
good
product
consist
comprehens
analysi
use
amp
recent
emerg
virus
west
nile
viru
wnv
sar
cov
cmv
could
bring
valu
amp
viru
inactivationintervent
strategi
gener
